메뉴 건너뛰기




Volumn 52, Issue 3, 2006, Pages 313-317

Results of a Phase II study of weekly docetaxel and carboplatin in Stage IIIB (with effusion) or Stage IV non-small cell lung cancer patients age ≤65 and performance status 2

Author keywords

Adult; Human; Multicenter; Poor prognosis

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DOCETAXEL;

EID: 33646478690     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.01.001     Document Type: Article
Times cited : (2)

References (20)
  • 1
    • 0027945314 scopus 로고
    • Current management of unresectable non-small cell lung cancer
    • [discussion 11-3]
    • Livingston R.B. Current management of unresectable non-small cell lung cancer. Semin Oncol 21 (1994) 4-11 [discussion 11-3]
    • (1994) Semin Oncol , vol.21 , pp. 4-11
    • Livingston, R.B.1
  • 2
    • 0036194111 scopus 로고    scopus 로고
    • Therapy for Stage IIIB and Stage IV non-small cell lung cancer
    • Kim T.E., and Murren J.R. Therapy for Stage IIIB and Stage IV non-small cell lung cancer. Clin Chest Med 23 (2002) 209-224
    • (2002) Clin Chest Med , vol.23 , pp. 209-224
    • Kim, T.E.1    Murren, J.R.2
  • 3
    • 0034220252 scopus 로고    scopus 로고
    • Chemotherapy in metastatic non-small-cell lung cancer
    • Sandler A. Chemotherapy in metastatic non-small-cell lung cancer. Oncology (Huntingt) 14 (2000) 15-27
    • (2000) Oncology (Huntingt) , vol.14 , pp. 15-27
    • Sandler, A.1
  • 4
    • 0028843552 scopus 로고
    • Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
    • Non-small Cell Lung Cancer Collaborative Group
    • Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311 (1995) 899-909
    • (1995) BMJ , vol.311 , pp. 899-909
  • 5
    • 0027367248 scopus 로고
    • Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?
    • Grilli R., Oxman A.D., and Julian J.A. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?. J Clin Oncol 11 (1993) 1866-1872
    • (1993) J Clin Oncol , vol.11 , pp. 1866-1872
    • Grilli, R.1    Oxman, A.D.2    Julian, J.A.3
  • 6
    • 0028031433 scopus 로고
    • Chemotherapy vs. supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature
    • Marino P., Pampallona S., Preatoni A., Cantoni A., and Invernizzi F. Chemotherapy vs. supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 106 (1994) 861-865
    • (1994) Chest , vol.106 , pp. 861-865
    • Marino, P.1    Pampallona, S.2    Preatoni, A.3    Cantoni, A.4    Invernizzi, F.5
  • 8
    • 0042413836 scopus 로고    scopus 로고
    • Randomized multimatrional, Phase III study of docetaxel plus platinum combinations versus vinorebline plus cisplatin for advanced non small cell lung cancer: the TAX 326 study group
    • Fossella F., Pereira J.R., von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., et al. Randomized multimatrional, Phase III study of docetaxel plus platinum combinations versus vinorebline plus cisplatin for advanced non small cell lung cancer: the TAX 326 study group. J Clin Oncol 21 (2003) 3016-3024
    • (2003) J Clin Oncol , vol.21 , pp. 3016-3024
    • Fossella, F.1    Pereira, J.R.2    von Pawel, J.3    Pluzanska, A.4    Gorbounova, V.5    Kaukel, E.6
  • 9
    • 0033369094 scopus 로고    scopus 로고
    • New options in the treatment of non-small cell lung cancer
    • Fossella F., Rigas J.R., and Belani C.P. New options in the treatment of non-small cell lung cancer. Anticancer Drugs 10 (1999) S25-S28
    • (1999) Anticancer Drugs , vol.10
    • Fossella, F.1    Rigas, J.R.2    Belani, C.P.3
  • 10
    • 1842715876 scopus 로고    scopus 로고
    • Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for Stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial
    • Choy H., DeVore R.F., Hande K.R., Porter L.L., Rosenblatt P.A., Slovis B., et al. Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for Stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial. Lung Cancer 34 (2001) 441-449
    • (2001) Lung Cancer , vol.34 , pp. 441-449
    • Choy, H.1    DeVore, R.F.2    Hande, K.R.3    Porter, L.L.4    Rosenblatt, P.A.5    Slovis, B.6
  • 11
    • 1542713370 scopus 로고    scopus 로고
    • Gefitnib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial-INTACT 2
    • Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., et al. Gefitnib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial-INTACT 2. J Clin Oncol 22 (2004) 785-794
    • (2004) J Clin Oncol , vol.22 , pp. 785-794
    • Herbst, R.S.1    Giaccone, G.2    Schiller, J.H.3    Natale, R.B.4    Miller, V.5    Manegold, C.6
  • 13
    • 33845382806 scopus 로고
    • Nonparametric estimation from incomplete observations
    • Kaplan E., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
    • (1958) J Am Stat Assoc , vol.53 , pp. 457-481
    • Kaplan, E.1    Meier, P.2
  • 15
    • 0035889915 scopus 로고    scopus 로고
    • Outcome of patients with a performance status of 2 in ECOG study E1594: a Phase III trial in patients with metastatic NSCLC
    • Sweeney C.J., Zhu J., Sandler A.B., Schiller J., Belani C.P., Langer C., et al. Outcome of patients with a performance status of 2 in ECOG study E1594: a Phase III trial in patients with metastatic NSCLC. Cancer 92 (2001) 2639-2647
    • (2001) Cancer , vol.92 , pp. 2639-2647
    • Sweeney, C.J.1    Zhu, J.2    Sandler, A.B.3    Schiller, J.4    Belani, C.P.5    Langer, C.6
  • 16
  • 17
    • 2342469070 scopus 로고    scopus 로고
    • Addressing the optimal number of cytotoxic agents in Stage IIA/IV NSCLC: a metanalysis of the published literature
    • Baggstrom M.Q., Socinski M.A., Hensing T.A., and Poole C. Addressing the optimal number of cytotoxic agents in Stage IIA/IV NSCLC: a metanalysis of the published literature. Proc Am Soc Clin Oncol 22 (2003) 624
    • (2003) Proc Am Soc Clin Oncol , vol.22 , pp. 624
    • Baggstrom, M.Q.1    Socinski, M.A.2    Hensing, T.A.3    Poole, C.4
  • 18
    • 0003275345 scopus 로고    scopus 로고
    • Single-agent vs. combination chemotherapy in advanced NSCLC: a CALGB randomized trial of efficacy, quality of life and cost effectiveness
    • Lilenbaum R.C., Herndon J., List M., Desch C., Watson D., Holland J., et al. Single-agent vs. combination chemotherapy in advanced NSCLC: a CALGB randomized trial of efficacy, quality of life and cost effectiveness. Proc Am Soc Clin Oncol 21 (2002) 2
    • (2002) Proc Am Soc Clin Oncol , vol.21 , pp. 2
    • Lilenbaum, R.C.1    Herndon, J.2    List, M.3    Desch, C.4    Watson, D.5    Holland, J.6
  • 19
    • 10044289201 scopus 로고    scopus 로고
    • Gemcitabine vs. gemcitabine carboplatin for patients with advanced NSCLC and PS 2. A prospective randomized Phase II study of the Hellemic Co-operative Oncology Group
    • Kosmidis P.A., Dimopoulos M.A., Syrigos C., Nicolaides C., Aravantinos G., Boukovinas I., et al. Gemcitabine vs. gemcitabine carboplatin for patients with advanced NSCLC and PS 2. A prospective randomized Phase II study of the Hellemic Co-operative Oncology Group. Proc Am Soc Clin Oncol 23 (2004) 627
    • (2004) Proc Am Soc Clin Oncol , vol.23 , pp. 627
    • Kosmidis, P.A.1    Dimopoulos, M.A.2    Syrigos, C.3    Nicolaides, C.4    Aravantinos, G.5    Boukovinas, I.6
  • 20
    • 10044272817 scopus 로고    scopus 로고
    • Preliminary results of a Phase II trial utilizing gemcitabine in patients with advanced non-small cell lung cancer and a performance status 2
    • Neubauer M.A., Reynolds C.H., Joppert M., Whittaker T., Ahmad Y.H., Ghaddar H., et al. Preliminary results of a Phase II trial utilizing gemcitabine in patients with advanced non-small cell lung cancer and a performance status 2. Proc Am Soc Clin Oncol 23 (2004) 643
    • (2004) Proc Am Soc Clin Oncol , vol.23 , pp. 643
    • Neubauer, M.A.1    Reynolds, C.H.2    Joppert, M.3    Whittaker, T.4    Ahmad, Y.H.5    Ghaddar, H.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.